<DOC>
	<DOCNO>NCT00330707</DOCNO>
	<brief_summary>To compare toxicity efficacy combination BCG interferon alpha standard dose low dose BCG alone high risk superficial bladder cancer</brief_summary>
	<brief_title>Combined Use BCG Interferon Alpha Bladder Cancer</brief_title>
	<detailed_description>140 eligible patient high risk superifical bladder cancer would randomise receive standard dose BCG , low dose BCG combination low dose BCG interferon alpha schedule `` 6+3 '' weekly intravesical instillation . Patients would closely monitor cystoscopy urine cytology intravenous urograms indicate . Pre-and post-instillation urine sample would collect cytokine analysis .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<criteria>( 1 ) Patients must completely resect , histologically ? proven urothelial carcinoma urinary bladder , stage Ta Tl 1 ? 16 week prior registration , and/or carcinomainsitu bladder biopsy . Central pathology review mandatory . ( 2 ) Patients Stage Ta urothelial carcinoma must judge increase risk tumor recurrence virtue one following : ( ) Tumor recurrence 56 week prior registration , ( b ) Two initial tumor within 28 week , ( c ) Grade III urothelial carcinoma 16 week prior registration , ( ) Dysplasia carcinomainsitu random biopsy ( e ) Positive urinary cytology post tumor resection . `` Suspicious '' `` suggestive '' cytology insufficient criterion . ( 3 ) Patients receive prior intravesical therapy BCG eligible provide undergone course intravesical agent within two month prior entry . ( 4 ) There age restriction ; however , patient register willing available 5 ? year follow life expectancy least two year . ( 5 ) Patients Karnofsky score &gt; 50 . ( 6 ) Women child ? bearing age use effective contraceptive method . ( 7 ) Patients agree take vitamin supplement ( except prescribe study ) duration trial . ( 8 ) Pretreatment laboratory test radiological examination must obtain 16 week prior patient registration . ( 9 ) All patient inform investigational nature study , sign write informed consent accordance institutional guideline . ( 1 ) Patients medical illness mental status , would preclude cooperation study . ( 2 ) Patients immunodeficient , receive immunosuppressive radiation therapy chemotherapy . ( 3 ) Patients urothelial carcinoma stage T2 high . ( 4 ) Patients evidence urothelial carcinoma upper urinary tract time recruitment . ( 5 ) Patients receive radiation therapy bladder cancer within one year prior registration . ( 6 ) Patients previously treat intravesical BCG . ( 7 ) Patients active tuberculosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>bladder cancer</keyword>
	<keyword>BCG</keyword>
	<keyword>interferon alpha</keyword>
</DOC>